Toward Minimal Residual Disease-Directed Therapy in Melanoma - Rambow F., Rogiers A, Aibar S, Dewaele M, Marin-Bejar O, Adriaens C, Talebi A, Wouters J, Radaelli E, Wolter P, Bechter O, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord JJ, Aerts S & Marine JC - 2018 - Cell - Pubmed

Identification of the tumour transition states occurring during EMT - Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Renvenco T, Boumahdi S, Van Keymeulen A, Brown D, Moers V, Lemaire S, de Clercq S, Minguijon-Perez E, Balsat C, Sokolow S, Dubois C, de Cock F, Scozzaro S, Lanas A, D’Haene N, Salmon I, Marine JC, Voet T, Sotiropoulou P & Blanpain C - 2018 - Nature - Pubmed

Mouse Cutaneous Melanoma Induced by Mutant BRaf Arises from Expansion and Dedifferentiation of Mature Pigmented Melanocytes - Köhler C, Nittner D, Rambow F, Radaelli E, Stanchi F, Niels Vandamme N, Baggiolini A, Sommer L, Berx G, van den Oord J, Gerhardt H, Blanpain C & Marine JC - 2017 - Cell Stem Cell - Pubmed

p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity - Adriaens C, Standaert L, Barra J, Latil M, Verfaillie A, Kalev P, Boeckx B, Wijnhoven PW, Radaelli E, Vermi W, Leucci E, Lapouge G, Beck B, van den Oord J, Nakagawa S, Hirose T, Sablina AA, Lambrechts D, Aerts S, Blanpain C, Marine JC - 2016 - Nat Med - Pubmed

Melanoma Addiction to the lncRNA SAMMSON - Leucci E, Vendramin R, Spinazzi M, Laurette P, Fiers M, Wouters J, Radaelli E, Eyckerman S, Leonelli C, Venderheyden K, Rogiers A, Hermans E, Baatsen P, Aerts S, Amant F, Van Aelst S, van den Oord J, de Strooper B, Davidson I, Lafontaine D, Gevaert K, Vandesompele Jo, Mestdagh P, & Marine JC - 2016 - Nature - Pubmed

Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation - Nittner D, Lambertz I, Clermont F, Mestdagh P, Köhler C, Nielsen SJ, Jochemsen A, Speleman F, Vandesompele J, Dyer MA, Schramm A, Schulte JH, Marine JC - 2012 - Nat Cell Biol - Pubmed

MDM4 is a key therapeutic target in cutaneous melanoma - Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, Moriceau G, Lo RS, Ghanem G, Shackleton M, Bernal F, Marine JC - 2012 - Nat Med - Pubmed